{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:25:35Z","timestamp":1775179535954,"version":"3.50.1"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"1149","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:p>Breast cancer is the most common cancer in females worldwide. Nuclear medicine plays an important role in patient management, not only in initial staging, but also during follow-up. Radiopharmaceuticals to study breast cancer have been used for over 50 years, and several of these are still used in clinical practice, according to the most recent guideline recommendations.<\/jats:p>\n               <jats:p>In this critical review, an overview of nuclear medicine procedures used during the last decades is presented. Current clinical indications of each of the conventional nuclear medicine and PET\/CT examinations are the focus of this review, and are objectively provided. Radionuclide therapies are also referred, mainly summarising the methods to palliate metastatic bone pain. Finally, recent developments and future perspectives in the field of nuclear medicine are discussed. In this context, the promising potential of new radiopharmaceuticals not only for diagnosis, but also for therapy, and the use of quantitative imaging features as potential biomarkers, are addressed.<\/jats:p>\n               <jats:p>Despite the long way nuclear medicine has gone through, it looks like it will continue to benefit clinical practice, paving the way to improve healthcare provided to patients with breast cancer.<\/jats:p>","DOI":"10.1259\/bjr.20221153","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T15:16:14Z","timestamp":1682435774000},"source":"Crossref","is-referenced-by-count":11,"title":["The current role of nuclear medicine in breast cancer"],"prefix":"10.1093","volume":"96","author":[{"given":"Sofia C.","family":"Vaz","sequence":"first","affiliation":[{"name":"Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation , Lisbon, Portugal"},{"name":"Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center , Leiden, The Netherlands"}]},{"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation , Lisbon, Portugal"}]},{"given":"Ricardo","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation , Lisbon, Portugal"}]},{"given":"Lenka M. Pereira","family":"Arias-Bouda","sequence":"additional","affiliation":[{"name":"Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center , Leiden, The Netherlands"},{"name":"Department of Nuclear Medicine, Alrijne Hospital , Leiderdorp, The Netherlands"}]},{"given":"Maria Jo\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation , Lisbon, Portugal"},{"name":"Faculdade de Medicina , Lisbon, Portugal"}]},{"given":"Lioe-Fee","family":"de Geus-Oei","sequence":"additional","affiliation":[{"name":"Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center , Leiden, The Netherlands"},{"name":"Biomedical Photonic Imaging Group, University of Twente , Enschede, The Netherlands"},{"name":"Department of Radiation Science & Technology, Delft University of Technology , Delft, The Netherlands"}]}],"member":"286","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"2024050216075090900_b1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024050216075090900_b2","first-page":"429","article-title":"Nuclear medicine in oncology","volume":"6","author":"Oliveira","year":"2018","journal-title":"Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization"},{"key":"2024050216075090900_b3","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200095","article-title":"Nuclear medicine and molecular imaging advances in the 21st century","volume":"93","author":"Vaz","year":"2020","journal-title":"Br J Radiol"},{"key":"2024050216075090900_b4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1054\/brst.2000.0214","article-title":"Nuclear medicine and breast cancer: A review of current strategies and novel therapies","volume":"10","author":"Berghammer","year":"2001","journal-title":"Breast"},{"key":"2024050216075090900_b5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0033-8389(05)70328-6","article-title":"The role of nuclear medicine in breast cancer detection: Functional breast imaging","volume":"39","author":"Khalkhali","year":"2001","journal-title":"Radiol Clin North Am"},{"key":"2024050216075090900_b6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"2024050216075090900_b7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2967\/jnmt.120.246405","article-title":"SNMMI procedure standard\/EANM guideline for gated equilibrium radionuclide angiography","volume":"48","author":"Farrell","year":"2020","journal-title":"J Nucl Med Technol"},{"key":"2024050216075090900_b8","article-title":"Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)","author":"Matthias","year":"2022","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"2024050216075090900_b9","first-page":"14N","article-title":"Appropriate use criteria for bone scintigraphy in prostate and breast cancer: Summary and excerpts","volume":"58","author":"Donohoe","year":"2017","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b10","author":"NCCN guidelines Breast Cancer","year":"2023"},{"key":"2024050216075090900_b11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2967\/jnmt.121.264204","article-title":"SNMMI procedure standard\/EANM practice guideline for molecular breast imaging with dedicated \u03b3 -cameras","volume":"50","author":"Hruska","year":"2022","journal-title":"J Nucl Med Technol"},{"key":"2024050216075090900_b12","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/cncr.24874","article-title":"Locoregional treatment of primary breast cancer: Consensus recommendations from an international expert panel","volume":"116","author":"Kaufmann","year":"2010","journal-title":"Cancer"},{"key":"2024050216075090900_b13","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1007\/s00259-013-2544-2","article-title":"The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer","volume":"40","author":"Giammarile","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b14","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/bjs.10986","article-title":"Meta-Analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer","volume":"105","author":"Tee","year":"2018","journal-title":"Br J Surg"},{"key":"2024050216075090900_b15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10549-012-2225-z","article-title":"Efficacy of \"radioguided occult lesion localisation\" (roll) versus \"wire-guided localisation\" (WGL) in breast conserving surgery for non-palpable breast cancer: A randomised controlled multicentre trial","volume":"136","author":"Postma","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2024050216075090900_b16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.breast.2013.09.007","article-title":"Sentinel node and occult lesion localization (SNOLL): A systematic review","volume":"22","author":"Ahmed","year":"2013","journal-title":"Breast"},{"key":"2024050216075090900_b17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/CAD.0b013e3283394624","article-title":"Anticancer therapy induced cardiotoxicity: Review of the literature","volume":"21","author":"Geiger","year":"2010","journal-title":"Anticancer Drugs"},{"key":"2024050216075090900_b18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.CIR.39.1.19","article-title":"Rapid sequential visualization of the heart and great vessels in man using the wide-field anger scintillation camera. Radioisotope-angiography following the injection of technetium-99m","volume":"39","author":"Mason","year":"1969","journal-title":"Circulation"},{"key":"2024050216075090900_b19","first-page":"170","article-title":"Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity","volume":"41","author":"de Geus-Oei","year":"2013","journal-title":"J Nucl Med Technol"},{"key":"2024050216075090900_b20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1148\/102.3.701","article-title":"99M Tc-labeled polyphosphate as a skeletal imaging agent","volume":"102","author":"Subramanian","year":"1972","journal-title":"Radiology"},{"key":"2024050216075090900_b21","first-page":"398","article-title":"SNMMI procedure standard for bone scintigraphy 4.0","volume":"46","author":"Bartel","year":"2018","journal-title":"J Nucl Med Technol"},{"key":"2024050216075090900_b22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","article-title":"The EANM practice guidelines for bone scintigraphy","volume":"43","author":"Van den Wyngaert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/annonc\/mdr397","article-title":"Imaging bone metastases in breast cancer: Evidence on comparative test accuracy","volume":"23","author":"Houssami","year":"2012","journal-title":"Ann Oncol"},{"key":"2024050216075090900_b24","unstructured":"NCCN\n          . National Comprehensive Cancer Network. Breast cancer. 2022. Available from: https:\/\/ www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"2024050216075090900_b25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.semnuclmed.2013.03.003","article-title":"Radionuclide methods and instrumentation for breast cancer detection and diagnosis","volume":"43","author":"Surti","year":"2013","journal-title":"Semin Nucl Med"},{"key":"2024050216075090900_b26","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.3390\/cancers14194619","article-title":"Breast-Specific gamma imaging: An added value in the diagnosis of breast cancer, a systematic review","volume":"14","author":"De Feo","year":"2022","journal-title":"Cancers"},{"key":"2024050216075090900_b27","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2214\/AJR.17.18083","article-title":"First clinical experience using stereotactic breast biopsy guided by 99mtc-sestamibi","volume":"209","author":"Collarino","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"2024050216075090900_b28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/M18-2147","article-title":"Screening for breast cancer in average-risk women: A guidance statement from the American College of physicians","volume":"170","author":"Qaseem","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024050216075090900_b29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"2024050216075090900_b30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0960-7404(93)90001-F","article-title":"Gamma-probe guided localization of lymph nodes","volume":"2","author":"Alex","year":"1993","journal-title":"Surg Oncol"},{"key":"2024050216075090900_b31","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1200\/JCO.2005.03.228","article-title":"Morbidity after sentinel lymph node biopsy in primary breast cancer: Results from a randomized controlled trial","volume":"23","author":"Purushotham","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024050216075090900_b32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejso.2008.01.034","article-title":"Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature","volume":"34","author":"van der Ploeg","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"2024050216075090900_b33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.semnuclmed.2013.02.004","article-title":"Status of sentinel lymph node for breast cancer","volume":"43","author":"Moncayo","year":"2013","journal-title":"Semin Nucl Med"},{"key":"2024050216075090900_b34","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2168.1999.01078.x","article-title":"Comparison of radioguided excision with wire localization of occult breast lesions","volume":"86","author":"Luini","year":"1999","journal-title":"Br J Surg"},{"key":"2024050216075090900_b35","first-page":"204","article-title":"Radioguided surgery of occult breast lesions","volume":"34","author":"Luini","year":"1998","journal-title":"Eur J Cancer"},{"key":"2024050216075090900_b36","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1245\/s10434-008-9994-y","article-title":"Simplified technique of radioguided occult lesion localization (roll) plus sentinel lymph node biopsy (SNOLL) in breast carcinoma","volume":"15","author":"Lavou\u00e9","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2024050216075090900_b37","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00259-015-3121-7","article-title":"IROLL: does 3-D radioguided occult lesion localization improve surgical management in early-stage breast cancer?","volume":"42","author":"Bluemel","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b38","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-015-3138-y","article-title":"(18) F-naf PET\/CT: EANM procedure guidelines for bone imaging","volume":"42","author":"Beheshti","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"2024050216075090900_b40","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"2024050216075090900_b41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4329\/wjr.v8.i2.200","article-title":"Comparisons between glucose analogue 2-deoxy-2- ((18) F) fluoro-D-glucose and (18) F-sodium fluoride positron emission tomography\/computed tomography in breast cancer patients with bone lesions","volume":"8","author":"Capitanio","year":"2016","journal-title":"World J Radiol"},{"key":"2024050216075090900_b42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40336-020-00363-3","article-title":"Comparison between 18F-FDG and 18F-naf PET imaging for assessing bone metastases in breast cancer patients: A literature review","volume":"8","author":"Taralli","year":"2020","journal-title":"Clin Transl Imaging"},{"key":"2024050216075090900_b43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b44","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1007\/s00259-009-1147-4","article-title":"Unexpected foci of 18F-FDG uptake in the breast detected by PET\/CT: Incidence and clinical significance","volume":"36","author":"Litmanovich","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b45","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1634\/theoncologist.2019-0427","article-title":"Lymph node imaging in patients with primary breast cancer: Concurrent diagnostic tools","volume":"25","author":"Marino","year":"2020","journal-title":"Oncologist"},{"key":"2024050216075090900_b46","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","article-title":"Preoperative staging of large primary breast cancer with [ 18 F ] fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures","volume":"26","author":"Fuster","year":"2008","journal-title":"JCO"},{"key":"2024050216075090900_b47","first-page":"1729","article-title":"Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis","volume":"35","author":"Nikpayam","year":"2015","journal-title":"Anticancer Res"},{"key":"2024050216075090900_b48","doi-asserted-by":"crossref","first-page":"17S","DOI":"10.2967\/jnumed.115.157859","article-title":"F-FDG PET\/CT for staging and restaging of breast cancer","volume":"57 Suppl 1","author":"Groheux","year":"2016","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ijrobp.2018.07.2025","article-title":"FDG\/PET-CT\u2013based lymph node atlas in breast cancer patients","volume":"103","author":"Borm","year":"2019","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"2024050216075090900_b50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2019.08.021","article-title":"Irradiation of regional lymph node areas in breast cancer \u2013 dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design","volume":"142","author":"Borm","year":"2020","journal-title":"Radiotherapy and Oncology"},{"key":"2024050216075090900_b51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.semnuclmed.2022.05.001","article-title":"FDG-pet\/ct for primary staging and detection of recurrence of breast cancer","volume":"52","author":"Groheux","year":"2022","journal-title":"Semin Nucl Med"},{"key":"2024050216075090900_b52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.112.106864","article-title":"18F-Fdg PET\/CT in staging patients with locally advanced or inflammatory breast cancer: Comparison to conventional staging","volume":"54","author":"Groheux","year":"2013","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b53","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1524-4741.2010.00987.x","article-title":"Additional value of PET-CT in staging of clinical stage IIb and III breast cancer","volume":"16","author":"Segaert","year":"2010","journal-title":"Breast J"},{"key":"2024050216075090900_b54","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1007\/s00330-015-3630-6","article-title":"(18) F-FDG PET\/CT for initial staging in breast cancer patients-is there a relevant impact on treatment planning compared to conventional staging modalities?","volume":"25","author":"Krammer","year":"2015","journal-title":"Eur Radiol"},{"key":"2024050216075090900_b55","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2020.7592","article-title":"Clinical utility of 18F-FDG PET\/CT in staging localized breast cancer before initiating preoperative systemic therapy","volume":"18","author":"Ko","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2024050216075090900_b56","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1245\/s10434-019-08194-x","article-title":"Response to letter to the editor: `` 18FDG-PET\/CT imaging in breast cancer patients with clinical stage IIb or higher.''","volume":"27","author":"Srour","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2024050216075090900_b57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00259-010-1626-7","article-title":"Tumour markers and FDG PET\/CT for prediction of disease relapse in patients with breast cancer","volume":"38","author":"Evangelista","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b58","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cncr.25727","article-title":"Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole-body 18FDG-PET\/CT imaging and impact on patient management","volume":"117","author":"Champion","year":"2011","journal-title":"Cancer"},{"key":"2024050216075090900_b59","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2967\/jnumed.115.154138","article-title":"Baseline tumor 18F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+\/HER2- breast cancer","volume":"56","author":"Groheux","year":"2015","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b60","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [ 18F ] -fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European organization for research and treatment of cancer (EORTC) PET study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"2024050216075090900_b61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199529","article-title":"Fdg PET\/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST","volume":"13","author":"Depardon","year":"2018","journal-title":"PLoS One"},{"key":"2024050216075090900_b62","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","article-title":"Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer","volume":"44","author":"Riedl","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.mric.2017.12.006","article-title":"Use of breast-specific PET scanners and comparison with MR imaging","volume":"26","author":"Narayanan","year":"2018","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"2024050216075090900_b64","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2214\/AJR.15.15371","article-title":"Evaluation of a hanging-breast PET system for primary tumor visualization in patients with stage I-III breast cancer: Comparison with standard PET\/CT","volume":"206","author":"Teixeira","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"2024050216075090900_b65","first-page":"92","article-title":"First clinical experience with a dedicated PET for hanging breast molecular imaging","volume":"57","author":"Koolen","year":"2013","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1524-4741.2010.01044.x","article-title":"PET-guided breast biopsy","volume":"17","author":"Kalinyak","year":"2011","journal-title":"Breast J"},{"key":"2024050216075090900_b67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1148\/radiology.169.1.3262228","article-title":"Breast cancer: PET imaging of estrogen receptors","volume":"169","author":"Mintun","year":"1988","journal-title":"Radiology"},{"key":"2024050216075090900_b68","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.semnuclmed.2022.03.002","article-title":"16\u03b1-18F-fluoro-17\u03b2-fluoroestradiol (fes): Clinical applications for patients with breast cancer","volume":"52","author":"Ulaner","year":"2022","journal-title":"Semin Nucl Med"},{"key":"2024050216075090900_b69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3181\/00379727-46-11899","article-title":"Biological investigations with radioactive calcium and strontium","volume":"46","author":"Pecher","year":"1941","journal-title":"Experimental Biology and Medicine"},{"key":"2024050216075090900_b70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000337634","article-title":"Radionuclide therapy of bone metastases","volume":"7","author":"Fischer","year":"2012","journal-title":"Breast Care (Basel)"},{"key":"2024050216075090900_b71","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00259-017-3745-x","article-title":"Hybrid 18F-FDG PET\/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy","volume":"44","author":"Goorts","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b72","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2967\/jnumed.115.170456","article-title":"Initial results of a prospective clinical trial of 18 f-fluciclovine PET\/CT in newly diagnosed invasive ductal and invasive lobular breast cancers","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2967\/jnumed.116.183335","article-title":"Prospective clinical trial of 18 F-fluciclovine PET\/CT for determining the response to neoadjuvant therapy in invasive ductal and invasive lobular breast cancers","volume":"58","author":"Ulaner","year":"2017","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b74","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2024050216075090900_b75","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: A comparative pilot study with the 18F-FDG PET\/CT","volume":"35","author":"K\u00f6mek","year":"2021","journal-title":"Ann Nucl Med"},{"key":"2024050216075090900_b76","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-In-Human human epidermal growth factor receptor 2\u2013targeted imaging using 89 zr-pertuzumab PET\/CT: Dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J Nucl Med"},{"key":"2024050216075090900_b77","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-018-4696-z","article-title":"Evaluation of [ 89zr ] trastuzumab-pet\/ct in differentiating HER2-positive from HER2-negative breast cancer","volume":"169","author":"Dehdashti","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2024050216075090900_b78","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/MNM.0000000000001472","article-title":"Analysis of absorbed dose in radioimmunotherapy with 177lu-trastuzumab using two different imaging scenarios: A pilot study","volume":"42","author":"Nautiyal","year":"2021","journal-title":"Nucl Med Commun"},{"key":"2024050216075090900_b79","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","article-title":"Prostate-Specific membrane antigen in breast cancer: A comprehensive evaluation of expression and a case report of radionuclide therapy","volume":"169","author":"Tolkach","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"2024050216075090900_b80","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [ 68ga ] ga-dota.sa.fapi pet\/ct-guided [ 177lu ] lu-dota.sa.fapi radionuclide therapy in an end-stage breast cancer patient: New frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b81","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jvir.2007.02.019","article-title":"90Y radioembolization of metastatic breast cancer to the liver: Toxicity, imaging response, survival","volume":"18","author":"Bangash","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"2024050216075090900_b82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/RLI.0000000000000197","article-title":"Positron emission tomography\/magnetic resonance imaging for local tumor staging in patients with primary breast cancer: A comparison with positron emission tomography\/computed tomography and magnetic resonance imaging","volume":"50","author":"Grueneisen","year":"2015","journal-title":"Invest Radiol"},{"key":"2024050216075090900_b83","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.ejrad.2014.09.008","article-title":"Simultaneous whole-bodysimultaneous whole-body","volume":"83","author":"Taneja","year":"2014","journal-title":"Eur J Radiol"},{"key":"2024050216075090900_b84","doi-asserted-by":"crossref","first-page":"1235429","DOI":"10.1155\/2016\/1235429","article-title":"Corrigendum to \u201cthe role of 18f-FDG PET\/CT and MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis.\u201d","volume":"2016","author":"Liu","year":"2016","journal-title":"Biomed Res Int"},{"key":"2024050216075090900_b85","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1007\/s00259-020-04801-2","article-title":"Prospective evaluation of whole-body MRI and 18F-FDG PET\/MRI in N and M staging of primary breast cancer patients","volume":"47","author":"Bruckmann","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b86","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00259-021-05502-0","article-title":"Comparison of nodal staging between CT, MRI, and [ 18F ] -fdg PET\/MRI in patients with newly diagnosed breast cancer","volume":"49","author":"Morawitz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b87","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/MNM.0000000000001254","article-title":"Diagnostic performance of PET\/computed tomography versus PET\/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients","volume":"41","author":"de Mooij","year":"2020","journal-title":"Nucl Med Commun"},{"key":"2024050216075090900_b88","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00330-018-5720-8","article-title":"What is the diagnostic performance of 18-FDG-PET\/MR compared to PET\/CT for the N- and m- staging of breast cancer?","volume":"29","author":"Botsikas","year":"2019","journal-title":"Eur Radiol"},{"key":"2024050216075090900_b89","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/bjc.2015.112","article-title":"Comparison of CE-FDG-PET\/CT with CE-FDG-PET\/MR in the evaluation of osseous metastases in breast cancer patients","volume":"112","author":"Catalano","year":"2015","journal-title":"Br J Cancer"},{"key":"2024050216075090900_b90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094017","article-title":"Relationship between tumor heterogeneity measured on FDG-PET\/CT and pathological prognostic factors in invasive breast cancer","volume":"9","author":"Soussan","year":"2014","journal-title":"PLoS One"},{"key":"2024050216075090900_b91","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-585","article-title":"Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast","volume":"14","author":"Son","year":"2014","journal-title":"BMC Cancer"},{"key":"2024050216075090900_b92","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s00259-019-04313-8","article-title":"Pet\/Ct radiomics in breast cancer: Promising tool for prediction of pathological response to neoadjuvant chemotherapy","volume":"46","author":"Antunovic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024050216075090900_b93","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01524-7","article-title":"Metabolic radiomics for pretreatment 18F-FDG PET\/CT to characterize locally advanced breast cancer: Histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis","volume":"7","author":"Ha","year":"2017","journal-title":"Sci Rep"},{"key":"2024050216075090900_b94","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1149\/20221153\/57370637\/bjr.20221153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/96\/1149\/20221153\/57370637\/bjr.20221153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:31:09Z","timestamp":1714674669000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20221153\/7469136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":94,"journal-issue":{"issue":"1149","published-online":{"date-parts":[[2023,4,26]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20221153","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,1]]},"published":{"date-parts":[[2023,4,26]]},"article-number":"20221153"}}